-
1
-
-
73349085919
-
Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
-
N.L. Spector, K.L. Blackwell Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 27 2009 5838 5847
-
(2009)
J Clin Oncol
, vol.27
, pp. 5838-5847
-
-
Spector, N.L.1
Blackwell, K.L.2
-
3
-
-
71049185479
-
Breast carcinoma - Rare types: Review of the literature
-
R. Yerushalmi, M.M. Hayes, K.A. Gelmon Breast carcinoma - rare types: review of the literature Ann Oncol 20 2009 1763 1770
-
(2009)
Ann Oncol
, vol.20
, pp. 1763-1770
-
-
Yerushalmi, R.1
Hayes, M.M.2
Gelmon, K.A.3
-
4
-
-
38449089721
-
Mucinous breast lesions: Diagnostic challenges
-
P.H. Tan, G.M. Tse, B.H. Bay Mucinous breast lesions: diagnostic challenges J Clin Pathol 61 2008 11 19
-
(2008)
J Clin Pathol
, vol.61
, pp. 11-19
-
-
Tan, P.H.1
Tse, G.M.2
Bay, B.H.3
-
5
-
-
51649096934
-
A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma
-
S. Di Saverio, J. Gutierrez, E. Avisar A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma Breast Cancer Res Treat 111 2008 541 547
-
(2008)
Breast Cancer Res Treat
, vol.111
, pp. 541-547
-
-
Di Saverio, S.1
Gutierrez, J.2
Avisar, E.3
-
6
-
-
52049107847
-
Mucinous breast carcinoma: A large contemporary series
-
C.R. Barkley, J.A. Ligibel, J.S. Wong Mucinous breast carcinoma: a large contemporary series Am J Surg 196 2008 549 551
-
(2008)
Am J Surg
, vol.196
, pp. 549-551
-
-
Barkley, C.R.1
Ligibel, J.A.2
Wong, J.S.3
-
7
-
-
0032895974
-
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas
-
S.G. Diab, G.M. Clark, C.K. Osborne Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas J Clin Oncol 17 1999 1442 1448
-
(1999)
J Clin Oncol
, vol.17
, pp. 1442-1448
-
-
Diab, S.G.1
Clark, G.M.2
Osborne, C.K.3
-
8
-
-
80053147913
-
Should liver metastases of breast cancer be biopsied to improve treatment choice?
-
G. Curigliano, V. Bagnardi, G. Viale Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 22 2011 2227 2233
-
(2011)
Ann Oncol
, vol.22
, pp. 2227-2233
-
-
Curigliano, G.1
Bagnardi, V.2
Viale, G.3
-
9
-
-
79960972539
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer
-
S. van de Ven, V.T. Smit, T.J. Dekker Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer Cancer Treat Rev 37 2011 422 430
-
(2011)
Cancer Treat Rev
, vol.37
, pp. 422-430
-
-
Van De Ven, S.1
Smit, V.T.2
Dekker, T.J.3
-
10
-
-
0038607569
-
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
-
X.F. Le, F.X. Claret, A. Lammayot The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition J Biol Chem 278 2003 23441 23450
-
(2003)
J Biol Chem
, vol.278
, pp. 23441-23450
-
-
Le, X.F.1
Claret, F.X.2
Lammayot, A.3
-
11
-
-
3543146052
-
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
-
W.J. Köstler, B. Schwab, C.F. Singer Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer Clin Cancer Res 10 2004 1618 1624
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1618-1624
-
-
Köstler, W.J.1
Schwab, B.2
Singer, C.F.3
-
12
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
Y. Lu, X. Zi, Y. Zhao Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 2001 1852 1857
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 1852-1857
-
-
Lu, Y.1
Zi, X.2
Zhao, Y.3
-
14
-
-
0037142184
-
Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance
-
S.A. Price-Schiavi, S. Jepson, P. Li Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance Int J Cancer 99 2002 783 791
-
(2002)
Int J Cancer
, vol.99
, pp. 783-791
-
-
Price-Schiavi, S.A.1
Jepson, S.2
Li, P.3
-
15
-
-
12544250996
-
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line
-
P. Nagy, E. Friedländer, M. Tanner Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line Cancer Res 65 2005 473 482
-
(2005)
Cancer Res
, vol.65
, pp. 473-482
-
-
Nagy, P.1
Friedländer, E.2
Tanner, M.3
-
16
-
-
0033135026
-
Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells
-
M. Komatsu, L. Yee, K.L. Carraway Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells Cancer Res 59 1999 2229 2236
-
(1999)
Cancer Res
, vol.59
, pp. 2229-2236
-
-
Komatsu, M.1
Yee, L.2
Carraway, K.L.3
-
17
-
-
0347123435
-
Mucins in cancer: Protection and control of the cell surface
-
M.A. Hollingsworth, B.J. Swanson Mucins in cancer: protection and control of the cell surface Nat Rev Cancer 4 2004 45 60
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 45-60
-
-
Hollingsworth, M.A.1
Swanson, B.J.2
|